According to GuruFocus Insider Data, these are the largest CEO buys during the past week.
Odonate Therapeutics CEO bought 769,231 shares
Odonate Therapeutics is a pharmaceutical company engaged in the development of therapeutics which improves and extend the lives of patients with cancer. It is developing tesetaxel, a chemotherapy agent used in the treatment of cancer. The company has a market cap of $756.13 million. Its shares traded at $28.27 as of June 21.
Net loss for the first quarter of 2019 was $28.65 million compared to $16.88 million for the comparable period of 2018.
Tang also bought 93,692 shares on June 5 at a price of $24.92; 76,308 shares on June 7 at a price of $27.36; and 50,000 shares on June 18 at a price of $26.15. The price of the stock has increased by 8.11% since.
10% Owner Boxer Capital LLC bought 384,615 shares on June 26 at a price of $26. The price of the stock has increased by 8.73% since.
Director Jeff L. Vacirca bought 19,231 shares on June 26 at a price of $26. The price of the stock has increased by 8.73% since.
Carnival PLC CEO bought 44,100 shares
Carnival Corporation (CCL) and Carnival plc (CUK, Financial) operate a dual listed company, where the businesses of each are combined and operate as one economic entity. Carnival is the largest global cruise company, with more than 100 ships on the seas. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe; P&O Cruises in Australia; and Fathom, supporting impact travel. Carnival also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attract more than 12 million guests annually. The company has a market cap of $31.68 billion. Its shares traded at $45.27 with a price-earnings ratio of 10.60 as of June 28.
Net income was $451 million for the second quarter of 2019 compared to net income of $561 million for the second quarter of 2018.
Donald bought 22,050 shares of CUK stock on June 25 at a price of $45.23. The price of the stock has increased by 0.09% since. Donald also bought 22,050 shares of CCL stock on June 25 at a price of $45.23. The price of the stock has increased by 2.92% since.
TG Therapeutics CEO bought 50,000 shares
TG Therapeutics is a U.S. biopharmaceutical company focused on the development and commercialization of B-cell malignancies and autoimmune disease treatments. The pipeline includes two treatments targeting hematological malignancies and autoimmune diseases: TG-1101 (ublituximab), a glycoengineered monoclonal antibody; and TGR-1202, an orally available PI3K delta inhibitor for various hematologic malignancies. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 now entering clinical development for autoimmune disorders. The company also has preclinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. The company has a market cap of $785.73 million. Its shares traded at $8.65 as of June 28.
Net loss was $35.2 million for the first quarter of 2019 compared to net loss of $41.5 million for the prior-year comparable period.
Liberty Latin America CEO bought 14,500 shares
Liberty Latin America is a telecommunications company. It offers communications and entertainment services including video, broadband internet, telephony and mobile services to its residential and business customers. The company has four reportable segments namely Cable and Wireless Communication, VTR and Liberty Puerto Rico. It generates a majority of its revenue from Cable and Wireless Communication. Geographically, the company gets a major share of its revenue from the United Kingdom. The company has a market cap of $3.14 billion. Its shares traded at $17.23 as of June 28.
Net loss for the three months ended March 31, 2019 was $42 million compared to $45 million for the three months ended March 31, 2018.
Senior Vice President and Chief Financial Officer Christopher J. Noyes bought 15,000 shares on June 27 at a price of $17.24. The price of the stock has decreased by 0.06% since.
Biohaven CEO bought 5,000 shares
Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. The company's product candidates are small molecules based on two distinct mechanistic platforms-calcitonin gene-related peptide, or CGRP, receptor antagonists and glutamate modulators-which it believes has the potential to significantly alter existing treatment approaches across a diverse set of neurological indications. The company has a market cap of $2.26 billion. Its shares traded at $43.79 as of June 28.
Net loss for the first quarter of 2019 was $62.3 million compared to $85.5 million for the first quarter of 2018.
Chief Financial Officer James Engelhart bought 2,500 shares on June 27 at a price of $43.05. The price of the stock has increased by 1.72% since.
Chief Medical Officer Robert Berman bought 2,500 shares on June 27 at a price of $42.3. The price of the stock has increased by 3.52% since.
Director John W. Childs bought 10,000 shares on June 26 at a price of $40.37. The price of the stock has increased by 8.47% since.
For the complete list of stocks that bought by their company CEOs, go to: CEO Buys.
Disclosure: I do not own stock in any of the companies mentioned.
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys:: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.